The CYP2C19*17 variant is not independently associated with clopidogrel response.
about
The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsPharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Antiplatelet drug interactions with proton pump inhibitorsEffectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase contentClinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Prospective Evaluation of Genetic Variation in Platelet Endothelial Aggregation Receptor 1 Reveals Aspirin-Dependent Effects on Platelet Aggregation Pathways.Clinical pharmacokinetics and pharmacodynamics of clopidogrel.Review of clopidogrel dose escalation in the current era of potent P2Y12 inhibitors.Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults.Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis.Genotyping of CYP2C19 polymorphisms and its clinical validation in the ethnic Arab population.Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.Clopidogrel dose adjustment after outpatient screening for CYP2C19 variant alleles: a pilot study.Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans.
P2860
Q26801867-93708805-3D36-4C5A-BC3A-EFC35B2CACE6Q26822796-E9C40446-1AC9-4F5C-A0BF-2032ADBEB9ABQ27022443-5A8519B8-0980-471F-AC88-2DA30333BA5DQ33948811-F5AABA72-6C7D-4A30-9DB7-075A234E0AC4Q33963651-93E5A8BE-8F2E-4C72-B7A3-C16EDEC075DEQ35719554-03077CE8-902F-4BFF-8C55-10EAEE02A7D5Q36643041-AD8F5139-8777-48C2-B52E-E0D5279D7AC6Q37107608-455CBE5D-754E-4ED1-834F-258A51AFF011Q37708007-39F1BB2B-6CAB-46DC-A681-63188F976FD6Q38307535-28C94D71-1095-4EE4-B20E-961AA38C6B84Q38532527-7D17F4E0-8BAF-4C0B-9778-8843BEB809F4Q40366712-20FB4F64-9803-4632-8F4D-544A05A1BEE8Q41356186-F72206CD-2190-46D1-91C6-65E9D94982D4Q41432957-BEE2F552-330C-4A4A-B3DE-42880CD8ADC8Q41706384-FF7E5775-6C74-4F74-963A-8E5A90A6282BQ47094164-CEC02646-1094-440A-98A8-F9DDA62D6B3DQ47232877-705AE383-9368-4744-95A5-33665F93C111Q47554139-759E4DA1-D064-4620-9A53-2535ABE601DAQ48217024-3B2C65E4-19D9-41EE-AEAC-319DC9BFEF1EQ49222788-5A7E5D51-CF90-41D4-9064-C1AE939673F6Q51072780-DCFF3B28-43BF-4D12-B03A-2E59E7A56298Q52589473-20A6A6C2-87D9-42EB-B84E-D88C5CEEF3C4Q53601038-358B3270-7B3A-4C95-9525-BC76F32A6F69
P2860
The CYP2C19*17 variant is not independently associated with clopidogrel response.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The CYP2C19*17 variant is not independently associated with clopidogrel response.
@en
The CYP2C19*17 variant is not independently associated with clopidogrel response.
@nl
type
label
The CYP2C19*17 variant is not independently associated with clopidogrel response.
@en
The CYP2C19*17 variant is not independently associated with clopidogrel response.
@nl
prefLabel
The CYP2C19*17 variant is not independently associated with clopidogrel response.
@en
The CYP2C19*17 variant is not independently associated with clopidogrel response.
@nl
P2093
P2860
P356
P1476
The CYP2C19*17 variant is not independently associated with clopidogrel response.
@en
P2093
J R O'Connell
M A Pacanowski
R B Horenstein
S D Spencer
S H Stephens
P2860
P304
P356
10.1111/JTH.12342
P577
2013-09-01T00:00:00Z